Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: A gynecologic oncology group study

Sutton, Gregory P.; Axelrod, Janice H.; Bundy, Brian N.; Roy, Tapan Kumar; Homesley, Howard D.; Malfetano, John H.; Mychalczak, Borys; King, Mary E.

doi:10.1016/j.ygyno.2005.03.011

Cited by 104 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…USCs account for 3–10% of endometrial carcinomas. While USCs represent a minority of total endometrial cancer cases they are responsible for a disproportionate number of deaths [3], [4]. They are high grade tumors with deep myometrial invasion and lymphovascular involvement [5].…”

Section: Introductionmentioning

confidence: 99%

Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma

et al. 2010

View full text Add to dashboard Cite

BackgroundEndometrial cancer is the most common gynecologic malignancy in developed countries and little is known about the underlying mechanism of stage and disease outcomes. The goal of this study was to identify differentially expressed genes (DEG) between late vs. early stage endometrioid adenocarcinoma (EAC) and uterine serous carcinoma (USC), as well as between disease outcomes in each of the two histological subtypes.Methodology/Principal FindingGene expression profiles of 20 cancer samples were analyzed (EAC = 10, USC = 10) using the human genome wide illumina bead microarrays. There was little overlap in the DEG sets between late vs. early stages in EAC and USC, and there was an insignificant overlap in DEG sets between good and poor prognosis in EAC and USC. Remarkably, there was no overlap between the stage-derived DEGs and the prognosis-derived DEGs for each of the two histological subtypes. Further functional annotation of differentially expressed genes showed that the composition of enriched function terms were different among different DEG sets. Gene expression differences for selected genes of various stages and outcomes were confirmed by qRT-PCR with a high validation rate.ConclusionThis data, although preliminary, suggests that there might be involvement of distinct groups of genes in tumor progression (late vs. early stage) in each of the EAC and USC. It also suggests that these genes are different from those involved in tumor outcome (good vs. poor prognosis). These involved genes, once clinically verified, may be important for predicting tumor progression and tumor outcome.

show abstract

Section: Introductionmentioning

confidence: 99%

Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The GOG (Gynecologists Oncology Group) has recently reported the outcome of performing adjuvant whole abdominal RT in the patients with stage III and IV endometrial cancer (15). Of the 180 evaluable patients who entered that study, 103 had high-risk histology, i.e., either papillary serous or clear cell cancers.…”

Section: Discussionmentioning

confidence: 99%

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

Kim

Lee

et al. 2006

Cancer Res Treat

View full text Add to dashboard Cite

“…Sutton ir kt. tyrimas parodė, kad esant III-IV endometriumo vėžio stadijai ir histologiškai nepalankiam tipui (šviesių ląstelių karcinoma, serozinė papilinė), išgyvenamumo trukmė ilgėja, kai yra taikoma išplėstinė abdominalinė radioterapija [28].…”

Section: Optimalus Endometriumo Vėžio Adjuvantinis Gydymasunclassified

Dubens ir paraaortinių limfmazgių pašalinimo svarba gydant ir stadijuojant endometriumo vėžį

Simavičius

Bogužienė

Černauskis

2015

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

Reikšminiai žodžiai: endometriumo vėžys, limfadenektomija, dubens limfmazgiai, paraaortiniai limfmazgiai, stadijavimas. Nuo 1988 metų endometriumo vėžys stadijuojamas chirurgiškai, tačiau ir po daugybės atliktų tyrimų ir praktikos limfadenektomijos reikšmė esant ankstyvos stadijos endometriumo vėžiui kelia nemažai klausimų. Atlikus chirurginį stadijavimą galima atrinkti pacientes tolesniam adekvačiam adjuvantiniam gydymui. Deja, netikslingai atlikta limfadenektomija lemia didesnį sergamumą ir mirtingumą. Yra atlikta nemažai tyrimų, vertinančių limfadenektomijos reikšmę gydant endometriumo vėžį, vis dėlto rezultatai yra dviprasmiški ir tai kelia daug diskusijų. Pagrindiniai klausimai, susiję su limfmazgių pašalinimu, yra tokie: kaip nuspėti galimą navikinio proceso plitimą limfmazgiuose ir kaip tikslingai atrinkti tas pacientes, kurioms limfmazgių pašalinimas reikalingas. Nors atlikti tyrimai esant ankstyvos stadijos endometriumo vėžiui nepatvirtina limfmazgių pašalinimo naudos, tačiau jų rezultatai kelia nemažai diskusijų. Tikėtina, kad ateityje sarginio limfmazgio identifikavimas išspręs nemažai diskusinių klausimų. Yra žinoma, kad limfadenektomija lemia didesnį sergamumą ir ekonomines išlaidas, tačiau įtaka ilgalaikei gyvenimo kokybei lieka neaiški. Svarbiausi šio straipsnio tikslai ir būtų įvardyti parametrus, lemiančius navikinio proceso plitimą limfmazgiuose, įvardyti sarginio limfmazgio reikšmę bei suprasti netikslingos limfadenektomijos įtaką sergamumui.

show abstract

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: A gynecologic oncology group study

Cited by 104 publications

References 19 publications

Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma

Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma

Patterns of Failure after Postoperative Radiation Therapy for Endometrial Carcinoma

Dubens ir paraaortinių limfmazgių pašalinimo svarba gydant ir stadijuojant endometriumo vėžį

Contact Info

Product

Resources

About